| Assessment Status | Rapid Review Complete |
| HTA ID | 23065 |
| Drug | Dapagliflozin |
| Brand | Forxiga® |
| Indication | Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%. |
| Assessment Process | |
| Rapid review commissioned | 11/10/2023 |
| Rapid review completed | 21/11/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dapagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. December 2023.
